Search

Displaying results 1971 - 1980 of 4300 in total
  1. Drug

    Dutasteride

    go.drugbank.com/drugs/DB01126
    ApprovedInvestigational

    It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. … Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to

  2. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    It was originally approved by the U.S.

  3. Drug

    Sulfacytine

    go.drugbank.com/drugs/DB01298
    Approved

    Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. … It inhibits bacterial synthesis of of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase.

  4. Drug

    Detomidine

    go.drugbank.com/drugs/DB11556
    InvestigationalVet approved

    This drug is prescribed by veterinarians and is marketed as _Dormosedan_. Currently, it is only approved by the FDA for use in horses but has been studied for use in other large animals.

  5. Drug

    Procaterol

    go.drugbank.com/drugs/DB01366
    ApprovedWithdrawn

    It is a potent bronchodilator that may be administered orally or by aerosol inhalation.

  6. Drug

    Drotrecogin alfa

    go.drugbank.com/drugs/DB00055
    ApprovedWithdrawn

    Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. … It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond.

  7. Drug

    Dihydroergotamine

    go.drugbank.com/drugs/DB00320
    ApprovedInvestigational

    [L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. … [A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution

  8. Drug

    Verteporfin

    go.drugbank.com/drugs/DB00460
    ApprovedInvestigational

    Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet

  9. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age. … [L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema.

  10. Drug

    Imipramine

    go.drugbank.com/drugs/DB00458
    ApprovedInvestigational

    In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood.